Trial Profile
A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary) ; Triamcinolone
- Indications Osteoarthritis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Flexion Therapeutics
- 18 Apr 2013 Data presented at the Osteoarthritis Research Society International's (OARSI) 2013 World Congress on Osteoarthritis, according to a Flexion Therapeutics media release.
- 17 Dec 2012 Results have been reported in a Flexion Therapeutics media release.
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.